JP2562827B2 - アジュバント混合物 - Google Patents
アジュバント混合物Info
- Publication number
- JP2562827B2 JP2562827B2 JP63063073A JP6307388A JP2562827B2 JP 2562827 B2 JP2562827 B2 JP 2562827B2 JP 63063073 A JP63063073 A JP 63063073A JP 6307388 A JP6307388 A JP 6307388A JP 2562827 B2 JP2562827 B2 JP 2562827B2
- Authority
- JP
- Japan
- Prior art keywords
- pathogen
- adjuvant
- adjuvant mixture
- oil
- polyoxypropylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002671 adjuvant Substances 0.000 title claims description 23
- 239000000203 mixture Substances 0.000 title claims description 18
- 244000052769 pathogen Species 0.000 claims description 22
- -1 polyoxypropylene Polymers 0.000 claims description 22
- 230000001717 pathogenic effect Effects 0.000 claims description 17
- 229920002125 Sokalan® Polymers 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 13
- 229920001451 polypropylene glycol Polymers 0.000 claims description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- 229920005862 polyol Polymers 0.000 claims description 8
- 150000003077 polyols Chemical class 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 6
- 241000287828 Gallus gallus Species 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 244000037640 animal pathogen Species 0.000 claims 2
- 229960001631 carbomer Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 13
- 229920001983 poloxamer Polymers 0.000 description 8
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920008712 Copo Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 229920002009 Pluronic® 31R1 Polymers 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940096529 carboxypolymethylene Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8700629 | 1987-03-17 | ||
| NL8700629 | 1987-03-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63253032A JPS63253032A (ja) | 1988-10-20 |
| JP2562827B2 true JP2562827B2 (ja) | 1996-12-11 |
Family
ID=19849718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63063073A Expired - Fee Related JP2562827B2 (ja) | 1987-03-17 | 1988-03-16 | アジュバント混合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5026543A (OSRAM) |
| EP (1) | EP0283085B1 (OSRAM) |
| JP (1) | JP2562827B2 (OSRAM) |
| DE (1) | DE3875762T2 (OSRAM) |
| DK (1) | DK167849B1 (OSRAM) |
| ES (1) | ES2052685T3 (OSRAM) |
| GR (1) | GR3007039T3 (OSRAM) |
| HU (1) | HU202119B (OSRAM) |
| ZA (1) | ZA881694B (OSRAM) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| EP0688205A1 (en) * | 1993-03-11 | 1995-12-27 | Secretech, Inc. | Polymeric mucoadhesives in the delivery of immunogens at mucosal surfaces |
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| WO1995011700A1 (en) * | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| GB9417742D0 (en) * | 1994-09-03 | 1994-10-19 | Univ Nottingham | Macrophage stimulating composition |
| BE1008977A5 (fr) * | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
| US5891393A (en) * | 1996-04-09 | 1999-04-06 | The University Of North Carolina At Chapel Hill | Method for the microbial decontamination of blood platelets |
| GB9622159D0 (en) * | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
| US6572874B1 (en) | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
| US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
| US6416779B1 (en) | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
| FR2776928B1 (fr) * | 1998-04-03 | 2000-06-23 | Merial Sas | Vaccins adn adjuves |
| ES2311451T3 (es) * | 1999-03-24 | 2009-02-16 | The Secretary Of State For Defence | Carbohidratos policationicos como immuestimulantes en vacunas. |
| US6943152B1 (en) * | 1999-06-10 | 2005-09-13 | Merial | DNA vaccine-PCV |
| MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
| US7018638B2 (en) | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
| US6676958B2 (en) * | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| CA2513655C (en) | 2003-01-21 | 2011-11-22 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
| ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
| EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
| CA2571421A1 (en) | 2004-06-24 | 2006-01-05 | Nicholas Valiante | Compounds for immunopotentiation |
| UA95602C2 (ru) | 2004-12-30 | 2011-08-25 | Берингер Ингельхейм Ветмедика, Инк. | Иммуногенная композиция цвс2 и способы приготовления такой композиции |
| US8097245B2 (en) | 2005-12-28 | 2012-01-17 | Advanced Bionutrition Corporation | Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same |
| AU2006338182B2 (en) | 2005-12-29 | 2013-08-22 | Boehringer Ingelheim Animal Health USA Inc. | Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs |
| TWI528970B (zh) | 2005-12-29 | 2016-04-11 | 百靈佳殷格翰家畜藥品公司 | 多價第二型豬環狀病毒（ｐｃｖ２）免疫組合物及製備該組合物之方法 |
| WO2007109813A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| EP2010530A2 (en) * | 2006-03-23 | 2009-01-07 | Novartis AG | Methods for the preparation of imidazole-containing compounds |
| ES2388556T3 (es) * | 2006-03-23 | 2012-10-16 | Novartis Ag | Compuestos inmunopotenciadores |
| EP2101815A4 (en) | 2006-12-11 | 2010-10-06 | Boehringer Ingelheim Vetmed | Effective method of treatment of porcine circovirus and lawsonia intracellularis infections |
| EP1941903A1 (en) | 2007-01-03 | 2008-07-09 | Boehringer Ingelheim Vetmedica Gmbh | Prophylaxis and treatment of PRDC |
| EP1958644A1 (en) | 2007-02-13 | 2008-08-20 | Boehringer Ingelheim Vetmedica Gmbh | Prevention and treatment of sub-clinical pcvd |
| US20080292663A1 (en) * | 2007-05-22 | 2008-11-27 | Gerber Jay D | Adjuvant compositions and methods for delivering vaccines |
| BRPI0907438A2 (pt) | 2008-01-23 | 2015-08-04 | Boehringer Ingelheim Vetmed | Composições imunogênicas para mycoplasma hyopneumoniae e pcv2 e métodos para produzir tais composições |
| TWI557117B (zh) | 2008-12-09 | 2016-11-11 | 吉李德科學股份有限公司 | 用於製備可用作類鐸受體調節劑之化合物的中間體化合物 |
| JP5762307B2 (ja) * | 2009-03-31 | 2015-08-12 | 国立感染症研究所長 | 経鼻投与用ワクチンを用いるインフルエンザの予防方法 |
| MX2011012586A (es) | 2009-05-26 | 2012-03-26 | Advanced Bionutrition Corp | Composicion de polvo seco estable que comprende microorganismos biologicamente activos y/o materiales bioactivos y metodos de elaboracion. |
| DK2529004T3 (en) | 2010-01-28 | 2017-09-25 | Advanced Bionutrition Corp | DRY GLASSY COMPOSITION INCLUDING A BIOACTIVE MATERIAL |
| US9504750B2 (en) | 2010-01-28 | 2016-11-29 | Advanced Bionutrition Corporation | Stabilizing composition for biological materials |
| CA3081072A1 (en) | 2012-03-12 | 2013-09-19 | Advanced Bioadjuvants, Llc | Adjuvant and vaccine compositions |
| UA114504C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
| UA114503C2 (uk) | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
| US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
| CA2924228C (en) | 2013-10-02 | 2024-01-16 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 orf2 protein variant and virus like particles composed thereof |
| WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
| PL3328215T3 (pl) | 2015-07-29 | 2021-12-13 | Advanced Bionutrition Corp. | Stabilne suche kompozycje probiotyczne do specjalnych zastosowań dietetycznych |
| US20210228713A1 (en) | 2018-06-04 | 2021-07-29 | Apros Therapeutics, Inc. | Tlr7 peptide conjugates |
| MX2020014087A (es) | 2018-07-02 | 2021-04-12 | Ayuvis Res Inc | Moléculas inmunomoduladoras pequeñas novedosas. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3178350A (en) * | 1961-05-15 | 1965-04-13 | Cutler Lab Inc | Biologic antigens adjuvanted with a colloidally water-soluble polymer of acrylic acidcrosslinked with polyallyl sucrose or polyallyl pentaerythritol |
| US3919411A (en) * | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
| US3869546A (en) * | 1972-12-22 | 1975-03-04 | Cutter Lab | Adjuvant compositions and medicinal mixtures comprising them |
| DE3308458A1 (de) * | 1983-03-10 | 1984-09-13 | Behringwerke Ag, 3550 Marburg | Verfahren zur adjuvierung von vaccinen |
| US4567043A (en) * | 1983-06-15 | 1986-01-28 | American Home Products Corporation (Del.) | Canine corona virus vaccine |
| US4567042A (en) * | 1983-06-15 | 1986-01-28 | American Home Products Corporation | Inactivated canine coronavirus vaccine |
| US4606918A (en) * | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
| US4772466A (en) * | 1983-08-22 | 1988-09-20 | Syntex (U.S.A.) Inc. | Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants |
-
1988
- 1988-03-09 EP EP88200443A patent/EP0283085B1/en not_active Expired - Lifetime
- 1988-03-09 ZA ZA881694A patent/ZA881694B/xx unknown
- 1988-03-09 ES ES88200443T patent/ES2052685T3/es not_active Expired - Lifetime
- 1988-03-09 DE DE8888200443T patent/DE3875762T2/de not_active Expired - Fee Related
- 1988-03-15 DK DK141488A patent/DK167849B1/da not_active IP Right Cessation
- 1988-03-16 HU HU881255A patent/HU202119B/hu not_active IP Right Cessation
- 1988-03-16 JP JP63063073A patent/JP2562827B2/ja not_active Expired - Fee Related
-
1989
- 1989-09-27 US US07/414,648 patent/US5026543A/en not_active Expired - Lifetime
-
1993
- 1993-02-11 GR GR930400270T patent/GR3007039T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK141488D0 (da) | 1988-03-15 |
| HU202119B (en) | 1991-02-28 |
| EP0283085B1 (en) | 1992-11-11 |
| JPS63253032A (ja) | 1988-10-20 |
| DE3875762T2 (de) | 1993-05-13 |
| GR3007039T3 (OSRAM) | 1993-07-30 |
| ES2052685T3 (es) | 1994-07-16 |
| ZA881694B (en) | 1988-09-06 |
| DE3875762D1 (de) | 1992-12-17 |
| US5026543A (en) | 1991-06-25 |
| DK167849B1 (da) | 1993-12-27 |
| EP0283085A1 (en) | 1988-09-21 |
| DK141488A (da) | 1988-09-18 |
| HUT47224A (en) | 1989-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2562827B2 (ja) | アジュバント混合物 | |
| JP5074656B2 (ja) | 改良されたマイコプラズマハイオニューモニエバクテリンワクチン | |
| US20080003201A1 (en) | Interleukin-12 as a veterinary vaccine adjuvant | |
| US5565209A (en) | Adjuvant mixture | |
| HU206989B (en) | Process for producing vaccines comprising tocols as adjuvant | |
| KR20050103215A (ko) | 보르데텔라 브론키셉티카에 대한 개 백신 | |
| JP2004536106A (ja) | マイコプラズマ・ボビスワクチンおよび動物の肺炎を減少させる方法 | |
| US20050202046A1 (en) | Canine vaccine for protection against ehrlichiosis | |
| Miao et al. | Enhanced immune response to rabies viruses by the use of a liposome adjuvant in vaccines | |
| US6936260B1 (en) | Vaccine composition | |
| CN110507819B (zh) | 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用 | |
| US20090087456A1 (en) | Adjuvanted vaccine | |
| JP5470052B2 (ja) | 動物の感染症を治療または予防するための免疫原組成物 | |
| JP2012504118A (ja) | ワクチンアジュバント | |
| Rehmani et al. | The influence of adjuvants on oral vaccination of chickens against Newcastle disease | |
| Babudieri et al. | Comparative tests with formolized and irradiated vaccines against leptospirosis | |
| Chen et al. | Comparison of the immune response to three different Yersinia pestis vaccines in guinea pigs and langurs | |
| Mutwiri et al. | ALEXANDER K. ANDRIANOV | |
| Okerman et al. | Failure of oil adjuvants to enhance immunity induced in mice by an inactivated rabbit Pasteurella multocida vaccine | |
| WO2023240278A2 (en) | Uses of glycolipids as a vaccine adjuvant and methods thereof | |
| EP0085469A1 (en) | Method of preparing an immunogen of Pasteurella multocida | |
| Basu et al. | Studies on immunomodulatory effect of levamisole and stressroak in chicks vaccinated with different Newcastle disease (ND) vaccines | |
| Montbrau et al. | EFFICACY OF ERAVAC® AGAINST A HETEROLOGOUS CHALLENGE WITH A VIRULENT RHDV-2 STRAIN IN THE PRESENCE AND/OR ABSENCE OF MATERNAL DERIVED ANTIBODIES | |
| AU2002335754A1 (en) | Interleukin-12 as a veterinary vaccine adjuvant | |
| WO1993004698A1 (en) | Method of enhancing anti-rabies immune responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |